DUBLIN--(BUSINESS WIRE)--Mainstay Medical today announced that the United States Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth ...
DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for ...
Mechanical chronic low back pain results from an injury or stress on the tissues surrounding the spine, including soft tissues, muscles, bones, and joints. Often, this type of pain is due to impaired ...
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota
DUBLIN, February 04, 2026--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 ...
Anyone living with chronic low back pain frequently has one wish on their mind: “Fix. My. Lower. Back.” Now, a new clinically proven restorative treatment option called ReActiv8 could make a ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results